About Cessatech
Cessatech is a pivotal-stage biotech company dedicated to rethinking medicines for children by addressing significant unmet paediatric needs, particularly in hospital and emergency settings. By repositioning well-known medicines into child-friendly formulations and delivery methods, Cessatech reduces development risk and accelerates time to market. Cessatech’s strategy is to grow the business through strong partnerships that support regulatory execution and commercial success across key markets. Cessatech is located in Hellerup, Denmark and led by a seasoned team with a proven track-record within drug development and product launches, in Europe, US and Asia.
Releases
See all
Releases
13. November, 2025
Financial Report Q3-2025
The Company has advanced well with its planned activities Closing the clinical and regulatory...
Releases
31. October, 2025
CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children
Successful completion of technology transfer of CT001 with STAQ Pharma supporting near term product...
Releases
21. August, 2025
Financial Report Q2-2025
The Company has advanced well with its planned activities Positive and clinical meaningful top-line...
Releases
14. August, 2025
Marketing Authorisation Application (MAA) for CT001 has been submitted to the European Medicines Agency (EMA) for acute pain management in children
The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency...
Releases
27. June, 2025
Cessatech Q&A – June company presentation
Selected top 5 summarized questions from investors… Q&A Cessatech_June
Releases
19. June, 2025
Strengthening Executive Management with the promotion of Martin Juhl
On 19 June – Cessatech A/S (“Cessatech” or “the Company”) and the Board of...
Releases
11. June, 2025
Completion of the directed issue of shares
As announced on 28 May 2025, the Board of directors in Cessatech exercised an...
Releases
28. May, 2025
Positive top-line results from its final CT001 Study 0202
On 28 May – Cessatech A/S (“Cessatech” or “the Company”) announces top-line results from...
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See detailsFacts about children
See all
Facts
2. December, 2025
Children deserve better prehospital pain treatment
A newly published registry study from the Region of Southern Denmark highlights a clear...
Facts
18. March, 2024
Acute pain treatment – large unmet need, paediatrics receive least…mainly due to inadequate solutions
More than 20 million children annually, alone in Europe, are subject to acute pain...
Facts
12. February, 2024
Treating children is not just like treating small adults
Giving medicine to children can’t be a one-size-fits-all approach. Their changing anatomy and...
Facts
25. August, 2023
New findings supporting CT001
Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...
Facts
15. March, 2022
Off-label use of medication in children continue to be the rule rather than the exception…
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...
Facts
3. March, 2022
Physical restraint of children in 79% of Scandinavian emergency departments
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
Facts
2. February, 2021
Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner
Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...
Facts
8. September, 2020
Behov for større sikkerhed omkring medicin til børn og unge i Danmark
Kun 30% af markedsførte lægemidler i EU er godkendt til børn, og kun 50%...